A new approach to protecting against HIV has shown early promise in laboratory testing. Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.

Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.

Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.